PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.41%
Revenue growth of 7.41% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
9.37%
Gross profit growth of 9.37% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
0.78%
Positive EBIT growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong competitive advantage in operations.
22.36%
Positive operating income growth while Medical - Pharmaceuticals is negative. Peter Lynch would spot a big relative advantage here.
5.48%
Positive net income growth while Medical - Pharmaceuticals median is negative. Peter Lynch would view this as a notable competitive advantage.
5.48%
Positive EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a strong advantage in per-share earnings compared to peers.
5.48%
Positive diluted EPS growth while Medical - Pharmaceuticals median is negative. Peter Lynch might see a real advantage in how this firm manages share count or drives net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.00%
10Y revenue/share CAGR near Medical - Pharmaceuticals median of 22.08%. Charlie Munger might expect stable industry trends guiding long-term growth.
-5.88%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see if others are at least growing moderately, indicating a firm-specific problem.
-32.18%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 6.34%. Seth Klarman would examine if the sector is otherwise stable, indicating a company-specific issue.
-100.00%
Negative 10Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-100.00%
Negative 5Y OCF/share CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
No Data
No Data available this quarter, please select a different quarter.
38.40%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 22.91% over a decade. Joel Greenblatt might see a standout compounder of earnings.
-5.96%
Negative 5Y CAGR while Medical - Pharmaceuticals median is 0.34%. Seth Klarman might see a specific weakness if peers maintain profitable expansions.
-29.07%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
90.52%
Equity/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 30.24% over 10 years. Joel Greenblatt would see if a high ROE underlies this compounding advantage.
28.29%
5Y equity/share CAGR 75-90% of Medical - Pharmaceuticals median. John Neff calls for higher returns or more efficient buybacks to match peers.
-15.26%
Negative 3Y equity/share growth while Medical - Pharmaceuticals median is 27.11%. Seth Klarman sees a short-term weakness if peers still expand net worth.
-41.67%
Dividend declines over 10 years while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would see a relative disadvantage if peers consistently raised payouts.
-50.00%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
16.67%
3Y dividend/share CAGR of 16.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
16779.31%
AR growth of 16779.31% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
3.78%
Inventory growth of 3.78% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
7.63%
Asset growth of 7.63% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
4.31%
BV/share growth of 4.31% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
12.23%
Debt growth of 12.23% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest difference that matters if interest coverage is tight.
No Data
No Data available this quarter, please select a different quarter.
-45.53%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.